Show / Hide Navigation

  • New OCD Blog

Call for Proposals 2022 

Our 2022 call for proposals is open!

We are launching our 2022 call for proposals seeking hard-to-fund projects that nevertheless have great potential to make a major impact for OCD.

The total budget size for the winning project will be £150,000 + a possible extra £50,000 if our fundraising campaign is successful. This is because we already have £150,000 secured from donors, while the remaining £50,000 will be raised through an international crowdfunding campaign. So you will need to apply for £200,000 maximum.

Our independent Scientific Advisory Board will judge projects according to the following criteria and questions:

1. Scientific validity: how strong is the science?
2. Clinical opportunity: does the project have potential to get a treatment for OCD rapidly into the clinic?
3. Team track record: how credible is the team implementing the project?
4. Crowdfundability: is the project suitable for crowdfunding?

In 2020 we ran our first call for proposals and our scientific panel chose the psilocybin research project as the winner. (https://www.orchardocd.org/research/calls-for- proposals/). We then ran a successful crowdfunding campaign that was matched by one of our donors. 

Please submit an application no more than three pages long, with the following sections:

  1. Summary of the project
  2. Key objectives
  3. Challenges and how they will be overcome
  4. The project team
  5. Timeline
  6. Budget breakdown

Please email your submissions (three pages max) to research@orchardocd.org.

The deadline for applications is Saturday 30th April at 5pm GMT. Read more here.

Learn about orchard ocd



About Orchard and OCD
Orchard is a charity focusing on developing treatments for patients suffering from obsessive-compulsive disorder (OCD), a serious mental illness. We work with academia, clinicians, pharmaceutical/biotech companies, government agencies, patients and other charities to fast-track the development of new and innovative treatments for OCD.

OCD is a common, chronic and severely disabling mental illness that affects at least a million people in the UK alone. It is characterised by intrusive thoughts (obsessions) and accompanying rituals (compulsions) aimed at reducing anxiety and distress. A significant proportion have what is informally known as Pure O, where the obsessions and compulsions are completely internalised and cause considerable distress.

Sixty per cent of OCD patients are also depressed and many are suicidal. The lifetime prevalence of OCD is 2-3 %. It affects all population groups regardless of gender and culture.

Treatment options for OCD consist of anti-depressant medications developed primarily for other mental disorders, as well as cognitive behavioural therapy. Both of these treatments take several months to start to have any effect, and medications have significant side effects. Moreover, up to 40% of patients do not respond and 50% need further treatment.

The economic impact of OCD on the individual, family and society is significant in terms of the direct cost of extensive treatments as well as the indirect cost related to lost productivity.

There is an urgent need for the development of new and better treatments, yet the field is severely underfunded. No research is carried out by the pharmaceutical industry, and funding for academic research is scarce and difficult to obtain. This is why we have set up Orchard in order to raise much-needed funding for OCD research.


Registered with the Charity Commission of England and Wales. Charity number 1174480.

"Orchard will accelerate the discovery and development of new treatments for OCD patients through its international partnerships with academia, industry, patients/families, and advocates. I strongly support Orchard's vision and commitment to help individuals suffering from OCD; I am delighted to contribute to their efforts." Carolyn Rodriguez, M.D., Ph.D. Director, Translational OCD Research Program. Assistant Professor of Psychiatry and Behavioural Sciences, Stanford University School of Medicine.
Twitter Facebook Email